Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacology of satralizumab in AQP4-IgG positive NMOSD
jRCT2051230006Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Serum and CSF IL-6 and sIL-6R pharmacodynamics. Started Feb 2024; status: completed.
02
Drugs
satralizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on jRCT2051230006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230006.